About Praxisgemeinschaft für Onkologie und Urologie
- Top Sponsors
- Top Collaborators
- Trials By Phase
- Recruitment Status
- Top Conditions
- Intervention Types
- Top Intervention Names
- Trials By Gender
Lead Sponsor
# Trials
iOMEDICO AG
2
Hoffmann-La Roche
1
Ipsen
1
Martin-Luther-Universität Halle-Wittenberg
1
Novacea
1
Technical University of Munich
1
Universität des Saarlandes
1
Clinical Trials at Praxisgemeinschaft für Onkologie und Urologie
During the past decade, Praxisgemeinschaft für Onkologie und Urologie conducted 4 clinical trials. In the 10-year time frame, 4 clinical trials started and 0 clinical trials were completed, i.e. on
average, 0% percent of trials that started reached the finish line to date. In the past 5 years, 1 clinical trials started and 0 clinical trials were completed. i.e. 0%
of trials that started reached the finish line.
Trials List
Trail ID
Brief Title
Start Date
Completion Date
Status
Enrollment
DN-101 in Combination With Docetaxel in Androgen-Independent Prostate Cancer (AIPC) (AIPC Study of Calcitriol Enhancing Taxotere [ASCENT-2])
2006-01-01
2007-11-01
Terminated
1,200
Efficacy of FOLFOX+Bevacizumab in Combination With Irinotecan in the Treatment of Metastatic Colorectal Cancer
2011-05-01
2018-08-15
Completed
250
Phase III Sequential Open-label Study to Evaluate the Efficacy and Safety of Sorafenib Followed by Pazopanib Versus Pazopanib Followed by Sorafenib in the Treatment of Advanced / Metastatic Renal Cell Carcinoma (SWITCH-II)
2012-05-01
Completed
544
Trial of Abiraterone Acetate Plus LHRH-therapy Versus Abiraterone Acetate Sparing LHRH-therapy in Patients With Progressive Chemotherapy-naïve Castration-resistant Prostate Cancer (SPARE)
2014-05-01
2019-04-01
Completed
68
The Effectiveness Of Atezolizumab In Patients With Locally-Advanced Or Metastatic Non-Small Cell Lung Cancer After Prior Chemotherapy
2018-05-30
2023-05-30
Active, not recruiting
359
Study of Cabozantinib as Monotherapy or in Combination With Nivolumab in Patients With Advanced or Metastatic Renal Cell Carcinoma Under Real-life Clinical Setting in 1st Line Treatment.
2018-09-24
2026-08-31
Recruiting
105
Impact of eHealth Monitoring on Overall Survival in Patients With Metastatic NSCLC / Extensive-stage SCLC / Advanced TNBC Under First-line Treatment With Atezolizumab Plus Chemotherapy
2019-07-10
2021-07-01
Completed
154
Clinical Research Platform on Decision Making and Clinical Impact of Biomarker-Driven Precision Oncology
2020-04-17
2023-06-30
Recruiting
500
Clinical Trials Sponsors and Collaborators
Out of the total clinical trials conducted in "Praxisgemeinschaft für Onkologie und Urologie" #1 sponsor was "iOMEDICO AG" with 2 trials, followed by "Hoffmann-La Roche" with 1 trials
sponsored, "Ipsen" with 1 trials sponsored, "Martin-Luther-Universität Halle-Wittenberg" with 1 trials sponsored and "Novacea"
with 1 trials sponsored. Other sponsors include -3 different institutions and
companies that sponsored additional 7 trials in total.
In terms of collaborators to trials, out of the total clinical trials conducted in "Praxisgemeinschaft für Onkologie und Urologie"
#1 collaborator was "Roche Pharma AG" with 3 trials as a collaborator and "Bristol-Myers Squibb" with 1 trials as a collaborator. Other collaborators include -2 different institutions and companies that were
collaborators in the rest 2 trials.
Clinical Trials Conditions at Praxisgemeinschaft für Onkologie und Urologie
According to Clinical.Site data, the most researched conditions in "Praxisgemeinschaft für Onkologie und Urologie" are
"Prostate Cancer" (2 trials), "Advanced (Locally Advanced and Inoperable or Metastatic), PD-L1 IC-positive TNBC" (1 trials), "Advanced Solid Tumors or Hematologic Malignancies" (1 trials), "Advanced or Metastatic Renal Cell Carcinoma" (1 trials) and "Extensive-stage Small Cell Lung Cancer" (1 trials). Many other conditions were trialed in "Praxisgemeinschaft für Onkologie und Urologie" in a lesser frequency.
Clinical Trials Intervention Types at Praxisgemeinschaft für Onkologie und Urologie
Most popular intervention types in "Praxisgemeinschaft für Onkologie und Urologie" are "Drug" (5 trials) and "Other" (1 trials). Other intervention types were less common.
The name of intervention was led by "5FU/LV, Oxaliplatin, Bevacizumab, Irinotecan" (1 trials), "Atezolizumab" (1 trials), "Oxaliplatin, 5FU/LV, Bevacizumab" (1 trials), "Pazopanib+Sorafenib" (1 trials) and "Sorafenib+Pazopanib" (1 trials). Other intervention names were less common.
Clinical Trials Genders at Praxisgemeinschaft für Onkologie und Urologie
The vast majority of trials in "Praxisgemeinschaft für Onkologie und Urologie" are
6 trials for "All" genders and 2 trials for "Male" genders.
Clinical Trials Status at Praxisgemeinschaft für Onkologie und Urologie
Currently, there are NaN active trials in "Praxisgemeinschaft für Onkologie und Urologie".
undefined are not yet recruiting,
2 are recruiting,
1 are Active, not recruiting,
and undefined are Enrolling by invitation.
In total, there were 4 completed trials in Praxisgemeinschaft für Onkologie und Urologie,
undefined suspended trials,
and 1 terminated clinical trials to date.
Out of the total trials that were conducted in Praxisgemeinschaft für Onkologie und Urologie, 0 "Phase 1"
clinical trials were conducted, 2 "Phase 2" clinical
trials and 2 "Phase 3" clinical trials were conducted as
well. "Phase 4" trials included 0 trials, and there were
also 0 trials that are defined as “Not Applicable".